Literature DB >> 9192753

Kinetic evidence of the regeneration of multilineage hematopoiesis from primitive cells in normal human bone marrow transplanted into immunodeficient mice.

J D Cashman1, T Lapidot, J C Wang, M Doedens, L D Shultz, P Lansdorp, J E Dick, C J Eaves.   

Abstract

Based on initial observations of human CD34+ Thy-1+ cells and long-term culture-initiating cells (LTC-IC) in the bone marrow of some sublethally irradiated severe combined immunodeficient (SCID) mice transplanted intravenously with normal human marrow cells, and the subsequent finding that the NOD/LtSz-scid/scid (NOD/SCID) mouse supports higher levels of human cell engraftment, we undertook a series of time course experiments to examine posttransplant changes in the number, tissue distribution, cycling activity, and in vivo differentiation pattern of various human hematopoietic progenitor cell populations in this latter mouse model. These studies showed typical rapid posttransplant recovery curves for human CD34- CD19+ (B-lineage) cells, CD34+ granulopoietic, erythroid, and multilineage colony-forming cells (CFC), LTC-IC, and CD34+ Thy-1+ cells from a small initial population representing <0.1% of the original transplant. The most primitive human cell populations reached maximum values at 5 weeks posttransplant, after which they declined. More mature cell types peaked after another 5 weeks and then declined. A 2-week course of thrice weekly injections of human Steel factor, interleukin (IL)-3, granulocyte-macrophage colony-stimulating factor (GM-CSF), and erythropoietin (administered just before the mice were killed for analysis) did not alter the pace of regeneration of either primitive or mature human hematopoietic cells, or their predominantly granulopoietic and B-lymphoid pattern of differentiation, although a significant enhancing effect on the level of human cell engraftment sustained after 3 months was noted. Cycling studies showed the human CFC present at 4 to 5 weeks posttransplant to be rapidly proliferating even in mice not given human growth factors. However, by 10 weeks and thereafter, only quiescent human CFC were detected; interestingly, even in mice that were given the 2-week course of growth factor injections. These studies indicate the use of this model for future analysis of the properties and in vivo regulation of primitive human hematopoietic cells that possess in vivo repopulating ability.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9192753

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  25 in total

1.  Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function.

Authors:  T Ponomaryov; A Peled; I Petit; R S Taichman; L Habler; J Sandbank; F Arenzana-Seisdedos; A Magerus; A Caruz; N Fujii; A Nagler; M Lahav; M Szyper-Kravitz; D Zipori; T Lapidot
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

2.  Previously undetected human hematopoietic cell populations with short-term repopulating activity selectively engraft NOD/SCID-beta2 microglobulin-null mice.

Authors:  H Glimm; W Eisterer; K Lee; J Cashman; T L Holyoake; F Nicolini; L D Shultz; C von Kalle; C J Eaves
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

3.  Expansion in vitro of transplantable human cord blood stem cells demonstrated using a quantitative assay of their lympho-myeloid repopulating activity in nonobese diabetic-scid/scid mice.

Authors:  E Conneally; J Cashman; A Petzer; C Eaves
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

4.  Transduction of human NOD/SCID-repopulating cells with both lymphoid and myeloid potential by foamy virus vectors.

Authors:  Neil C Josephson; George Vassilopoulos; Grant D Trobridge; Greg V Priestley; Brent L Wood; Thalia Papayannopoulou; David W Russell
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-11       Impact factor: 11.205

Review 5.  Role of transcription factors C/EBPalpha and PU.1 in normal hematopoiesis and leukemia.

Authors:  Steffen Koschmieder; Frank Rosenbauer; Ulrich Steidl; Bronwyn M Owens; Daniel G Tenen
Journal:  Int J Hematol       Date:  2005-06       Impact factor: 2.490

Review 6.  A primitive cell origin for B-cell precursor ALL?

Authors:  C V Cox; A Blair
Journal:  Stem Cell Rev       Date:  2005       Impact factor: 5.739

Review 7.  Hematopoietic stem cells.

Authors:  Robert G Hawley; Ali Ramezani; Teresa S Hawley
Journal:  Methods Enzymol       Date:  2006       Impact factor: 1.600

8.  Fluorophore-conjugated iron oxide nanoparticle labeling and analysis of engrafting human hematopoietic stem cells.

Authors:  Dustin J Maxwell; Jesper Bonde; David A Hess; Sarah A Hohm; Ryan Lahey; Ping Zhou; Michael H Creer; David Piwnica-Worms; Jan A Nolta
Journal:  Stem Cells       Date:  2007-11-29       Impact factor: 6.277

9.  Comparison of Human Hematopoietic Reconstitution in Different Strains of Immunodeficient Mice.

Authors:  Ashley I Beyer; Marcus O Muench
Journal:  Stem Cells Dev       Date:  2016-10-27       Impact factor: 3.272

10.  MYC and PIM2 co-expression in mouse bone marrow cells readily establishes permanent myeloid cell lines that can induce lethal myeloid sarcoma in vivo.

Authors:  Su Hwa Jang; Hee Yong Chung
Journal:  Mol Cells       Date:  2012-07-26       Impact factor: 5.034

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.